Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr115.85M

Enterprise Valuekr107.45

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.23

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding111,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetMaintaining no reported debt materially reduces structural financial risk and interest obligations. Over a multi-month horizon this preserves flexibility to prioritize R&D or manufacturing investment, and lowers bankruptcy/default risk compared with leveraged peers.

Multi-year Revenue GrowthSustained top-line expansion over several years signals improving commercial traction for products and services. This trend supports scaling manufacturing and cell-banking operations, and provides a base to work toward sustainable margins as operations mature.

Vertical Cell-therapy CapabilitiesOwning cell-banking and manufacturing plus a focused ProTrans program creates durable competitive advantages: high technical barriers, service revenue potential, and integration between R&D and production that can protect margins and support commercialization pathways.

Bears Say

High Cash BurnPersistent large negative operating and free cash flows mean the company depends on external capital to fund operations. Over 2-6 months this raises dilution and refinancing risk and constrains the ability to fund clinical programs without new financing.

Sustained UnprofitabilityRepeated negative gross profit and sizeable net losses indicate the business model has not yet reached scalable, profitable operations. This structural unprofitability implies continued investment is needed before margins can normalize, pressuring long-term viability without clear breakeven paths.

Erosion Of Equity / Dilution RiskA multiyear decline in equity signals repeated financing or losses eroding book value, increasing shareholder dilution risk. Structurally this weakens the capital base and could limit strategic optionality or increase cost of future equity financings.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr115.85M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 111,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.